BioPorto adds Mr. Nis Kruse as EVP of Strategic Partnerships and GM of EMEA & APAC
December 5, 2022
News Release
BioPorto adds Mr. Nis Kruse as EVP of Strategic Partnerships and GM of EMEA & APAC
COPENHAGEN, DENMARK and BOSTON, MA, December 5, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) today announced that Mr. Nis Kruse joined the Company as EVP of Strategic Partnerships and General Manager of EMEA & APAC. He will also serve as site leader for the Hellerup, Denmark office.
“We are preparing for the prospective global launch of NGAL tests, having submitted our De Novo application to the US Food and Drug Administration to aid in identifying pediatric patients at risk of moderate to severe Acute Kidney Injury (AKI),” said Tony Pare, BioPorto’s CEO. “Nis’ experience in strategic partnership development, distributor management, and building commercial teams will be a welcome addition to the BioPorto executive team.”
Mr. Kruse most recently served as SVP & Chief Commercial Officer at SSI Diagnostica A/S, an in vitro diagnostics company focusing on infectious diseases, having delivered substantial topline growth in the company during the COVID pandemic. Previously, Mr. Kruse operated in a US-based position as Executive Director, Global Precision Medicine at Merck & Co., where he was responsible for Commercial Diagnostic Strategy and Commercial Partner Management related to Keytruda® across its numerous indications in immuno-oncology.
Earlier in his career, Mr. Kruse held leadership roles in Copenhagen at Agilent Technologies, H. Lundbeck, and AstraZeneca. Mr. Kruse holds Master’s and Bachelor’s degrees in Economics and Business Management from University of Aarhus (Denmark).
“I am excited to join BioPorto at this key juncture in advancing NGAL tests into routine clinical use,” remarked Mr. Kruse. “I look forward to contributing my leadership experience and commercial launch insight to the Company’s already robust management team in helping address the persistent, high, and unmet medical need to effectively detect and treat AKI.”
Mr. Kruse and his family are based in Copenhagen, and he will operate from the Company’s Hellerup office.
For investor inquiries, please contact:
Tim Eriksen, EU Investor Relations, Zenith Advisory, +45 4529 0000, [email protected]
Ashley R. Robinson, US Investor Relations, LifeSci Advisors, +1 617 430 7577, [email protected]
About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship product, The NGAL TestTM, is designed to aid in the risk assessment of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The NGAL Test is CE marked and registered in several countries worldwide.
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.
Forward-looking statement disclaimer
Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company’s expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts, including with respect to potential FDA marketing authorizations and global launch and commercialization of NGAL tests; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company’s ability to successfully market both new and existing products. These forward-looking statements, which may use words such as “aim”, “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company’s business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto’s success are more fully disclosed in BioPorto’s periodic financial filings with the Danish Financial Supervisory Authority, particularly under the heading “Risk Factors”.
